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Reply to “The Dual Personality of Iron Chelators: Growth Inhibitors
or Promoters?”
Daniel V. Zurawski, Anna C. Jacobs, Mitchell G. Thompson, Thomas J. Palys
Department of Wound Infections, Division of Bacterial and Rickettsial Disease, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
In their letter, Visca et al. have shown that P. aeruginosa can usedeferiprone as an iron “carrier,” which in turn promotes bacte-
rial growth in a low-iron M9 minimal medium (1). Since our
initial publication, we have also observed that the presence of
deferiprone (and some other iron chelators) at sub-MICs can pro-
mote the growth of clinical isolates of Acinetobacter baumannii in
M9 minimal medium (our unpublished results). However, while
these data are in agreement with the results published by de Lésé-
leuc et al. with respect to deferiprone and A. baumannii (2), in our
hands, they were also strain and chelator dependent. For example,
we did not observe growth promotion with VK28 and A. bauman-
nii (unpublished results). We agree with Visca et al. that the con-
sequences of growth promoted by iron chelators at sub-MIC levels
in minimal media need to be considered before clinical applica-
tion. However, it is unclear how relevant these findings would be
in vivo if a high-enough concentration of a chelator can be
achieved (1MIC). With systemic applications, these concen-
trations are not possible because of toxicity concerns, but for
wound infections, a topical, nonsystemic application could be
considered and was also highlighted in a recent review (3).
It should also be noted that our original intent was to investi-
gate the utility of iron chelators in combination with the current
standard of care with respect to war wound infections. The current
standard of care to treat devastating extremity wounds suffered by
U.S. military personnel includes broad-spectrum antibiotic treat-
ment and often negative-pressure wound therapy. Other groups
have shown that iron chelators in combination with antibiotics
against several bacterial species in vitro resulted in a significant
increase in bacterial killing, due in some cases to biofilm dispersal
(4–7). Our approach, while similar, relied on more recently devel-
oped iron chelators (i.e., VK28 and Apo6619) (8), and we actively
sought out the synergy with various conventional antibiotics. This
approach has led to the discovery that, while some iron chelators
have a high MIC alone against common, nosocomial bacteria (8),
they also have a synergistic effect with specific antibiotics against
A. baumannii (A. C. Jacobs, M. G. Thompson, B. W. Corey, and
D. V. Zurawski, unpublished data) and other bacteria (D. V. Zu-
rawski, U.S. patent application PCT/US12/23377). Some of these
data have been presented at recent meetings (9, 10).
In light of many studies and years of research regarding iron
chelators as antimicrobials, including both the failures and suc-
cesses in vitro and in vivo, it is clear that many factors will contrib-
ute to their potential utility. While caution should be employed,
we should still consider the prospect of using iron chelators in
specific clinical settings. Clearly the choice of chelator, bacterial
susceptibility, the application (i.e., systemic versus nonsystemic),
and the potential of synergy, whether it be with conventional an-
tibiotics or with other antibacterial therapies, will all need to be
considered in order to optimize therapeutic potential. Given the
unrelenting emergence of multidrug-resistant bacteria and the
growing lack of treatment options, further research is still war-
ranted.
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